Monaco Asset Management SAM Lowers Stock Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Monaco Asset Management SAM trimmed its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 27.7% in the 4th quarter, Holdings Channel.com reports. The firm owned 1,212,743 shares of the biotechnology company’s stock after selling 465,674 shares during the period. Monaco Asset Management SAM’s holdings in Heron Therapeutics were worth $1,855,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Anfield Capital Management LLC increased its position in shares of Heron Therapeutics by 5.6% during the fourth quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 6,264 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Heron Therapeutics by 21.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 45,273 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 7,927 shares in the last quarter. King Wealth Management Group boosted its stake in Heron Therapeutics by 52.3% during the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 8,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock worth $1,692,000 after purchasing an additional 9,418 shares in the last quarter. Finally, Glenmede Trust Co. NA raised its stake in shares of Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 10,578 shares during the last quarter. 80.01% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $2.32 on Friday. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The stock has a market capitalization of $353.41 million, a PE ratio of -12.89 and a beta of 1.55. The business’s fifty day moving average is $1.82 and its 200 day moving average is $1.74.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to the consensus estimate of $37.37 million. As a group, sell-side analysts expect that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Analyst Ratings Changes

HRTX has been the topic of several recent analyst reports. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research report on Friday, February 28th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.